Pacira BioSciences (PCRX) Non-Current Debt (2010 - 2026)

Pacira BioSciences' Non-Current Debt history runs 10 years deep, the most recent figure standing at $367.7 million for Q1 2026.

• In Q1 2026, Non-Current Debt rose 262.26% year-over-year to $367.7 million; the TTM figure through Mar 2026 stood at $367.7 million (up 262.26% YoY), while the FY2025 annual figure was $372.2 million, down 2.96% from the prior year.
• Non-Current Debt was $367.7 million for Q1 2026 at Pacira BioSciences, down from $372.2 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $383.5 million in Q4 2024 to a low of $97.8 million in Q2 2025.
• Historically, Non-Current Debt has averaged $220.0 million across 5 years, with a median of $137.5 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Non-Current Debt sank 61.93% in 2023, then surged 262.26% in 2026.
• A 5-year view of Non-Current Debt shows it stood at $251.1 million in 2022, then sank by 54.11% to $115.2 million in 2023, then surged by 232.93% to $383.5 million in 2024, then decreased by 2.96% to $372.2 million in 2025, then declined by 1.22% to $367.7 million in 2026.
• The last three Non-Current Debt figures came in at $367.7 million (Q1 2026), $372.2 million (Q4 2025), and $376.7 million (Q3 2025), per Business Quant data.